REALQUALITY RQ-PML-RARα bcr3 One-Step

REALQUALITY RQ-PML-RARα bcr3 One-Step is a molecular diagnostic kit designed for the
detection of the PML-RARα bcr3 transcript associated with
Acute Promyelocytic Leukemia (APL) and the t(15;17) translocation.
It uses a One-Step Real-Time RT-PCR format that allows fast, sensitive, and streamlined analysis.
This method reduces hands-on time and improves workflow efficiency in molecular laboratories.

The detection of bcr3 transcripts is essential for APL diagnosis and follow-up because it supports rapid
clinical decision-making. Furthermore, early identification of transcript levels helps clinicians monitor
treatment response and track Minimal Residual Disease (MRD). The One-Step design simplifies RNA handling,
reduces contamination risk, and ensures consistent performance across multiple assays.

Key Features of REALQUALITY RQ-PML-RARα bcr3 One-Step

Developed according to international guidelines for APL molecular monitoring
Specific detection of the bcr3 transcript from the PML-RARα fusion
Includes an internal fluorescent normalizer for enhanced quality control
Features a dUTP/UNG system to prevent PCR carryover contamination
Requires only 5 µL of extracted RNA for analysis
Shares a unified thermal profile with other PML-RARα assays for easier parallel runs
Suitable for treatment response monitoring and MRD detection in APL patients

Compatible With

REALQUALITY RQ-PML-RARα bcr3 STANDARD
Provides quantitative calibration and supports standard curve generation
for accurate MRD tracking.

🇮🇷 Exclusive Distribution in Iran

Fardad Azma Rad Co. is the exclusive representative
of AB Analitica in Iran. The company supplies the One-Step kit to diagnostic and research centers
across the country. It ensures:

Guaranteed authenticity of all imported kits
Specialized training for laboratory personnel
Scientific and technical support by experienced specialists
Fast and reliable distribution across Iran

This One-Step assay is an essential tool for laboratories seeking accurate and standardized detection of
PML-RARα bcr3 transcripts. It improves workflow simplicity, enhances diagnostic reliability, and supports
better clinical outcomes in APL management.

Download Catalog

Additional Information:
The t(15;17)(q22;q21) translocation is commonly associated with Acute Promyelocytic Leukemia (APL), a subtype of Acute Myeloid Leukemia (AML) with M3 morphology. APL accounts for approximately 10-15% of AML cases. This translocation results from the fusion of the PML gene (located on chromosome 15q22) and the RARa gene (located on chromosome 17q21). The breakpoint in the RARa gene is located within a 15 kb region of intron 2, while the breakpoint in the PML gene can occur in three different regions: intron 6 (55% of cases), intron 3 (40% of cases), and exon 6 (5% of cases). Each breakpoint is associated with a specific PML-RARa isoform named bcr1, bcr3, and bcr2, respectively. The fusion protein acts as a transcriptional repressor, blocking differentiation of hematopoietic stem cells and arresting them at the promyelocytic stage. Treatment with ATRA (All-Trans Retinoic Acid) is highly effective in APL, acting as an inducer of differentiation.